Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:55:17 EDT Thu 02 May 2024
Enter Symbol
or Name
USA
CA



Q:ORMP - ORAMED PHARMACEUTICALS INC - http://www.oramed.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ORMP - Q0.12.23·2.370.12.34+0.020.944.0873542.29  2.415  2.25015.25  1.6718:01:01Mar 1915 min RT 2¢

Recent Trades - Last 10 of 354
Time ETExPriceChangeVolume
18:01:01Q2.23-0.091
16:17:38Q2.350.031
16:16:42Q2.29-0.035
16:07:54Q2.34870.02871
16:00:00Q2.340.02182
16:00:00Q2.340.02100
16:00:00Q2.340.0241
16:00:00Q2.340.021
16:00:00Q2.340.0273
16:00:00Q2.340.0214

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-03-19 09:00U:ORMPNews ReleaseScilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation
2024-02-20 08:30U:ORMPNews ReleaseOramed Letter to Shareholders
2023-09-22 11:38U:ORMPNews ReleaseSorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company
2023-09-21 18:11U:ORMPNews ReleaseOramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company
2023-09-21 16:05U:ORMPNews ReleaseScilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.
2023-09-13 09:00U:ORMPNews ReleaseScilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder
2023-08-02 07:45U:ORMPNews ReleaseOramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally
2023-06-20 07:55U:ORMPNews ReleaseOramed to Present at the 83rd American Diabetes Association Conference
2023-05-18 07:55U:ORMPNews ReleaseOramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit
2023-05-15 09:05U:ORMPNews ReleaseOramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China